Tel Aviv - Delayed Quote • ILA
Evogene Ltd. (EVGN.TA)
At close: April 25 at 2:24 PM GMT+3
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -0.09 | -0.12 | -0.41 | -0.33 |
Low Estimate | -0.09 | -0.12 | -0.41 | -0.33 |
High Estimate | -0.09 | -0.12 | -0.41 | -0.33 |
Year Ago EPS | -0.15 | -0.17 | -0.52 | -0.41 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | 3.5M | 2.5M | 17M | 31.5M |
Low Estimate | 3.5M | 2.5M | 17M | 31.5M |
High Estimate | 3.5M | 2.5M | 17M | 31.5M |
Year Ago Sales | 641k | 720k | 5.64M | 17M |
Sales Growth (year/est) | 446.00% | 247.20% | 201.40% | 85.30% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.2 | -0.18 | -0.15 | -0.14 |
EPS Actual | -0.15 | -0.17 | -0.08 | -0.13 |
Difference | 0.05 | 0.01 | 0.07 | 0.01 |
Surprise % | 25.00% | 5.60% | 46.70% | 7.10% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.09 | -0.12 | -0.41 | -0.33 |
7 Days Ago | -0.09 | -0.12 | -0.41 | -0.33 |
30 Days Ago | -0.09 | -0.12 | -0.41 | -0.33 |
60 Days Ago | -0.07 | -0.07 | -0.3 | -0.26 |
90 Days Ago | -0.07 | -0.07 | -0.3 | -0.26 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | EVGN.TA | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 40.00% | -- | -- | 6.50% |
Next Qtr. | 29.40% | -- | -- | 12.00% |
Current Year | 21.20% | -- | -- | 5.30% |
Next Year | 19.50% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Initiated | Alliance Global Partners: Buy | 10/2/2023 |
Maintains | Lake Street: Buy to Buy | 8/18/2023 |
Maintains | Roth MKM: Buy to Buy | 7/21/2023 |
Initiated | Lake Street: Buy | 5/2/2023 |
Maintains | Aegis Capital: Buy | 9/12/2022 |
Maintains | Roth MKM: Buy to Buy | 9/2/2022 |
Related Tickers
CANF.TA Can-Fite BioPharma Ltd.
2.7000
+3.85%
PPBT.TA Purple Biotech Ltd
20.50
+1.99%
CGEN.TA Compugen Ltd.
764.00
+1.93%
BLRX.TA BioLineRx Ltd.
16.40
-2.38%
PPBT Purple Biotech Ltd
0.4900
-2.00%
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
GNTA Genenta Science S.p.A.
2.5900
-11.60%
PLUR Pluri Inc.
5.36
+2.23%
MURA Mural Oncology plc
3.5800
+1.42%
PHRM.CN PharmaTher Holdings Ltd.
0.2400
-2.04%